AlphAIAlphAI — Financial news for AI agents
investing.comOCT 282 min read$BLCO

Bausch + Lomb Q3 2026 slides: strong beat drives third guidance raise

Bausch + Lomb (BLCO) reported Q3 2026 revenue of $1.375B (+8% YoY), adjusted EBITDA of $325M (+34% YoY), and EPS of $0.34, beating estimates. The company raised full-year guidance, citing strong growth across all segments, particularly in dry eye treatments and premium IOLs. Shares rose 4.31% premarket.

Original reporting
investing.com
Published Oct 28, 2026, 1:19 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 28, 2026, 1:30 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$BLCO
Bullish
high confidence
Mentioned
$BLCO
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$BLCOBullishHigh
01

Why it matters

The earnings beat and guidance lift reinforce the company's growth trajectory, likely supporting further price appreciation.

02

Market read

Strong earnings and guidance raise make BLCO a near‑term buying candidate for healthcare‑focused traders.

03

What to watch

Potential headwinds from supply‑chain constraints or competitive pricing in dry‑eye market.

Relevance 8/10Novelty 8/10Timing: pre‑market today

Background

Bausch + Lomb (BLCO) is a leading eye‑care company with segments in pharmaceuticals, vision care, and surgical devices.

Company-level read

Ticker impact

$BLCOBullishHigh confidence
Context

BLCO reported Q3 2026 earnings beat and raised full-year guidance for the third time this year.

Expected impact

likely upside as investors price in stronger earnings and higher guidance

Evidence & confidence

Revenue and adjusted EBITDA beat expectations, free cash flow hit record levels, and guidance was lifted, driving demand.

Market effects

Sector

Eye‑care and ophthalmic devices sector may see broader rally on strong peer performance.

Regional

U.S. healthcare stocks could benefit from the upbeat earnings.

Global

Limited to U.S. markets; no immediate global macro effect.

Counterpoint

What could challenge this read

If the guidance raise is already priced in, the stock could face a short‑term pull‑back.

Key entities

  • Executive
    Thomas J. Appio

    Interim CEO and Chairman steering the company through strong quarterly performance.

Read at source← All news

StoryBausch + Lomb posts Q3 profit and lifts full‑year 2026 guidance

Also covered by

6 outlets

Related articles

OCT 28
$BLCOHighAI 9/10

Why is Bausch + Lomb stock surging today?

Bausch + Lomb (BLCO) stock rose 7.3% after Q3 2026 earnings beat estimates, with adjusted EPS of $0.34 vs. $0.21 expected, and revenue of $1.375B, up 7% YoY. The company raised full-year guidance for the third time, citing growth across all segments and improved profitability. The stock reached a 52-week high of $19.09.

investing.com2 min
OCT 28
$BLCOMedAI 8/10

Bausch + Lomb (BLCO) Q3 2026 Earnings Call Transcript

Bausch + Lomb (BLCO) reported Q3 2026 earnings with 8% revenue growth to $1.375B, 34% adjusted EBITDA increase, and 23.6% margin. All segments grew: Pharmaceuticals +11%, Surgical +9%, Vision Care +6%. The company reduced net leverage to 4.1x and remains confident in meeting its 3-year plan targets.

finance.yahoo.com2 min
OCT 28
$BLCOHighAI 8/10

Bausch + Lomb Posts 7% Revenue Growth, Raises 2026 Guidance

Bausch + Lomb reported Q3 2026 revenue of $1.375B, up 7% YoY, and net income of $32M. Adjusted EBITDA was $325M, and adjusted diluted EPS was $0.34. The company raised full-year revenue guidance to $5.45B–$5.55B and adjusted EBITDA guidance to $1.09B–$1.14B. All business segments grew, with notable increases in MIEBO and LUMIFY revenues.

tradingview.com1 min